Scott Gottlieb

Scott Gottlieb is Independent Chairman at Illumina, Inc. since 2025.
Independent Director at Pfizer Inc. since 2019.
Director at Wesleyan University, The Mount Sinai Health System, Inc., The Mount Sinai Medical Center, Inc., National Resilience, Inc., National Academy of Medicine (United States), Comanche Biopharma Corp.
since 2023, Xaira Therapeutics, Inc. since 2024.
Independent Director at Tempus AI, Inc. since 2019, Partner at New Enterprise Associates, Inc. since 2019, Special Partner at NEA Management Co. LLC since 2019, and Independent Director at UnitedHealth Group, Inc. since 2025.
Formerly Independent Director at CombiMatrix Corp.
from 2009 to 2016, Managing Director at T.R.
Winston & Co. LLC from 2013 to 2017, Independent Member of the Board of Directors at Bravo Health, Inc. from 2009 to 2011, Member of the Board of Directors at MedAvante, Inc. from 2007 to 2017, Independent Member of the Board of Directors at Molecular Insight Pharmaceuticals, Inc. from 2007 to 2010, Director at Aseko, Inc. and Targeted Medical Pharma, Inc., Director at EMI Holding, Inc. in 2015, Independent Member of the Board of Directors at American Pathology Partners, Inc. from 2012 to 2017, Member of the Board of Directors at Gradalis, Inc. from 2015 to 2017, Director at Tolero Pharmaceuticals, Inc. from 2015 to 2016, Independent Member of the Board of Directors at Daiichi Sankyo, Inc. from 2015 to 2017, Member of the Board of Directors at Aptiv Solutions, Inc. from 2012 to 2014, Analyst at Alex.
Brown & Sons, Inc. from 1994 to 1995, Senior Adviser to the Administrator at Centers for Medicare & Medicaid Services (US), Deputy Commissioner-Medical & Scientific Affairs at US Food & Drug Administration from 2005 to 2007, and Commissioner at US Food & Drug Administration from 2017 to 2019.
Education includes undergraduate degree from Wesleyan University and doctorate from Icahn School of Medicine at Mount Sinai.